Skip to main content
OncoTargets and Therapy logoLink to OncoTargets and Therapy
. 2021 Jan 8;14:123. doi: 10.2147/OTT.S296761

Exosomal miR-638 Inhibits Hepatocellular Carcinoma Progression by Targeting SP1 [Retraction]

PMCID: PMC7802791  PMID: 33447053

Yang J, Li B, Zhao S, Du H, Du Y. Onco Targets Ther. 2020;13:6709–6720.

At the request of the author, the Editor and Publisher of OncoTargets and Therapy wish to retract the published paper.

Following a review of their paper the authors have determined that due to a lack of data they can no longer confirm this study showed an anti-cancer role of exosome miR-638 in hepatocellular carcinoma (HCC) by inhibiting angiogenesis. The authors also confirmed they could no longer locate the original data for this study. In the interests of scientific integrity, the authors have agreed it best to retract the published article.

The Editor has determined the findings of the paper are no longer valid and has agreed with the authors request to retract the article.

The author wished to apologise for this error.

Our decision-making was informed by our policy on publishing ethics and integrity and the COPE guidelines on retraction.

The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as “Retracted”.


Articles from OncoTargets and therapy are provided here courtesy of Dove Press

RESOURCES